Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?

The Pharmacogenomics Journal volume 8, pages 315–320 (2008)Cite this article

A Corrigendum to this article was published on 20 May 2009

Abstract

The identification of clinical and genetic parameters to predict the outcome in advanced colorectal cancer is a key issue in the management of this disease. We ascertained whether the clinical determinants of survival defined in a large cohort of patients treated with 5-fluorouracil (5-FU) (European Organization for the Research and Treatment of Cancer, EORTC model) also apply to 109 colorectal cancer patients receiving a therapy including oxaliplatin/5-FU as their first-line treatment. Our results confirm the considerable discriminatory power of the clinical model proposed in patients treated with a combined chemotherapy regimen. With the aim of identifying additional genetic prognostic parameters, we determined whether the polymorphisms in the promoter region of the thymidylate synthase (TS) gene that modifies the number of operative binding sites of a transcription factor (USF) could predict the clinical outcome of our patients and complement the EORTC clinical model. Our results indicate that this new genetic parameter (the number of USF-binding sites) could be considered when evaluating the role of TS genotype in the efficacy of the 5-FU-based regimens. Further, confirmatory studies aimed at evaluating the effect of the number of binding sites of transcription factors for selecting 5-FU-treated patients are warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Grem JL . 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drug 2000; 18: 299–313.

    Article  CAS  Google Scholar 

  2. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al. Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059–2069.

    Article  CAS  PubMed  Google Scholar 

  3. Danenberg PV . Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473: 73–92.

    CAS  PubMed  Google Scholar 

  4. Longley DB, Harkin DP, Johnston PG . 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.

    Article  CAS  PubMed  Google Scholar 

  5. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308–317.

    Article  PubMed  Google Scholar 

  6. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65–70.

    Article  CAS  PubMed  Google Scholar 

  7. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779–1786.

    Article  CAS  PubMed  Google Scholar 

  8. Marsh S, McKay JA, Cassidy J, McLeod HL . Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383–386.

    CAS  PubMed  Google Scholar 

  9. Marcuello E, Altés A, Del Rio E, Cesar A, Menoyo A, Baiget M . Single nucleotide polymorphism in the 3′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 112: 733–737.

    Article  CAS  PubMed  Google Scholar 

  10. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R . Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611–1615.

    CAS  PubMed  Google Scholar 

  11. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785–792.

    Article  CAS  Google Scholar 

  12. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J . Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365–1369.

    Article  CAS  PubMed  Google Scholar 

  13. Marcuello E, Altés A, Menoyo A, del Rio E, Baiget M . Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57: 835–840.

    Article  CAS  PubMed  Google Scholar 

  14. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555–558.

    Article  CAS  PubMed  Google Scholar 

  15. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for the thymidylate synthase. Cell Struct Funct 1995; 20: 191–197.

    Article  CAS  PubMed  Google Scholar 

  16. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7: 4096–4101.

    CAS  PubMed  Google Scholar 

  17. Kawakami K, Omura K, Kanehira E, Watanabe Y . Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3249–3252.

    CAS  PubMed  Google Scholar 

  18. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898–2904.

    CAS  PubMed  Google Scholar 

  19. Kawakami K, Watanabe G . Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004–6007.

    CAS  PubMed  Google Scholar 

  20. Gusella M, Bolzonella C, Crepaldi G, Ferrazzi E, Padrini R . A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 2006; 6: 421–424.

    Article  CAS  PubMed  Google Scholar 

  21. Ulrich C, Bigler J, Velicer C, Greene E, Farin F, Potter J . Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomark Prev 2000; 9: 1381–1385.

    CAS  Google Scholar 

  22. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14: 319–327.

    Article  CAS  Google Scholar 

  23. Suh KW, Kim JH, Kim YB, Kim J, Jeong S . Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg 2005; 9: 336–342.

    Article  PubMed  Google Scholar 

  24. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM . Genomic copy number changes affecting the thymidylate synthase gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006; 66: 9369–9373.

    Article  CAS  PubMed  Google Scholar 

  25. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J . Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007; 17: 325–328.

    CAS  PubMed  Google Scholar 

  26. World Health Organization. Handbook for Reporting Results of Cancer Treatment.Publication no 48. World Health Organization: Geneva, Switzerland, 1979.

  27. Miller SA, Dykes DD, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1989; 16: 1215.

    Article  Google Scholar 

  28. Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24: 1603–1611.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Fondo de Investigación Sanitaria (PI 05/1218).

Author information

Authors and Affiliations

  1. Department of Genetics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    L Paré, E del Rio, L Sedano & M Baiget

  2. Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    E Marcuello & A Barnadas

  3. Department of Hematology, Hospital de l'Esperit Sant, Sta Coloma de Gramanet, Barcelona, Spain

    A Altés

  4. Ciberer, Juan Martorell 1, 46010 Valencia, ISCIII, Spain

    M Baiget

Authors
  1. L Paré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Marcuello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Altés
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E del Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Sedano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Baiget
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Baiget.

Additional information

Duality of interest

The authors declare no duality of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paré, L., Marcuello, E., Altés, A. et al. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?. Pharmacogenomics J 8, 315–320 (2008). https://doi.org/10.1038/sj.tpj.6500469

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500469

Keywords

This article is cited by

Search

Advanced search

Quick links